Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
TORONTO and HOUSTON, June 11, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA) (OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced that Dr....
-MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- -Up to 10-fold expansion of cancer-killing immune cells in non-human...
-Tumor control achieved in 76% of evaluable subjects irrespective of IL4R expression resulting in mOS, mPFS and PFS-12 of 15.0 months, 4.6 months and 33%, respectively- -In the Proposed Population...
- End of Phase 2 meeting package for MDNA55 to be submitted in Q2 2020- - IND submission for IL-2 Superkine Platform calendar Q1 2021- - Two abstracts to be presented at ASCO 2020- TORONTO and...
Data from MDNA55 Clinical Program and IL-2 Superkine Program TORONTO and HOUSTON, May 4, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical ...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ Funds to be Dedicated for Advancing IL-2 Superkine Programs TORONTO and HOUSTON, April 15, 2020 /CNW/ - ...
Conference call and webcast today at 10:00AM EST to discuss MDNA19 results with pre-clinical experts showing robust immune responses without toxicity TORONTO and HOUSTON, March 25, 2020 /CNW/ -...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, March 17, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, March 12, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, March 4, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company")...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, March 3, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company")...
TORONTO and HOUSTON, Feb. 13, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial...
Survival improvement of over 150% seen in MDNA55 subjects compared to a Synthetic Control Arm TORONTO and HOUSTON, Jan 13, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company")...
TORONTO and HOUSTON, Jan. 8, 2020 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has...
- MDNA55 achieves up to 5 fold increase in 12 month survival rate in aggressive, chemotherapy resistant glioblastoma when compared to approved therapies TORONTO and HOUSTON, Dec. 12, 2019 /CNW/ -...
Presentation Will Provide Update on Survival Trends in Various Population Subgroups Medicenna to also Present at the LD Micro Investor Conference TORONTO and HOUSTON, Dec. 9, 2019 /CNW/ - Medicenna...
- Tumor control rate of 82% in recurrent glioblastoma following one treatment with MDNA55 - Median overall survival of 15 months in patients over-expressing the IL4R - Meetings with regulatory...
Results presented at the 3rd SNO-SCIDOT Joint Conference show 12-month survival benefit of over 111% in patients over-expressing the IL-4 receptor TORONTO and HOUSTON, Nov. 21, 2019 /CNW/ - Medicenna ...
TORONTO and HOUSTON, Nov. 20, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it...
Event to feature renowned leaders in the field of immunotherapy and neuro-oncology TORONTO and HOUSTON, Nov. 18, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,...
Key Opinion Leaders Will Provide Updated Results on Efficacy, Safety and Delivery of MDNA55 TORONTO and HOUSTON, Nov. 14, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company")...
TORONTO and HOUSTON, Nov. 5, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, Oct. 17, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company")...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, Oct. 11, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company")...
/NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES./ TORONTO and HOUSTON, Oct. 2, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company")...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.